BRAVECTO® TriUNO chewable tablets for dogs
Bravecto TriUNO is the newest addition to the Bravecto family, protecting dogs from 8 weeks of age against fleas, ticks and worms including lungworm in a monthly chewable tablet.
Bravecto TriUNO provides a perfect start for puppies into the Bravecto family, moving to
Bravecto long-duration options from 6 months of age for tailored year-round protection.
Presentation
Light pink to light brown coloured, mottled, round-shaped chewable tablets.
Active ingredients
| BRAVECTO TriUNO chewable tablets for dogs |
Fluralaner (mg) |
Moxidectin (mg) | Pyrantel (as embonate) (mg) |
| 1.27–2.5 kg | 25 | 0.0625 | 12.5 |
| > 2.5–5 kg | 50 | 0.125 | 25 |
| > 5–10 kg | 100 | 0.25 | 50 |
| > 10–20 kg | 200 | 0.5 | 100 |
| > 20–40 kg | 400 | 1 | 200 |
| > 40–60 kg | 600 | 1.5 | 300 |
Target species
Dogs
Indications for use
For dogs with, or at risk from, mixed parasitic infestations by ticks or fleas, gastrointestinal nematodes, lungworm and/or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks or fleas, one or more of the target gastrointestinal nematodes, and prevention of either heartworm or lungworm disease, are all indicated at the same time.
For the treatment of tick and flea infestations on dogs providing immediate and persistent flea (Ctenocephalides felis and C. canis) and tick (Dermacentor reticulatus, Ixodes hexagonus, I. ricinus, and Rhipicephalus sanguineus) killing activity for 1 month.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
For reduction of the risk of infection with Babesia canis canis via transmission by D. reticulatus for 1 month. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
For reduction of the risk of infection with Dipylidium caninum via transmission by C. felis for 1 month. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
Treatment of infections with gastrointestinal nematodes of the following species:
roundworms (adult stages of Toxocara canis and Toxascaris leonina), hookworms (L4, immature adult (L5) and adult stages of Ancylostoma caninum and adult stages of Uncinaria stenocephala).
Prevention of heartworm disease (caused by Dirofilaria immitis).
Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).
Treatment of infections with Angiostrongylus vasorum (the causative agent of angiostrongylosis).
Bravecto TriUNO dogs can be used from 8 weeks of age and 1.27 kg in bodyweight.
Packaging
Carton with aluminium foil blister sealed with PET aluminium foil lid stock.
One cardboard box contains 1, 3 or 6 chewable tablets.
Not all pack sizes may be marketed.
Legal Category
POM-V
Frequently Asked Questions
-
Does Bravecto® have any breed specific contraindications?
There are no breed contraindications for this product. Any contraindications are listed in the product datasheet under Clinical particulars.
-
Bravecto® dosing and a growing puppy
A growing dog should be dosed with a tablet appropriate to the body weight at the time of treatment.
Field studies conducted in support of Bravecto’s marketing authorisation included growing dogs and there was no evidence for a lack of efficacy1,2. Bravecto showed continuous flea efficacy of >99% throughout the 12-week interval in these dogs. The minimum retreatment interval for dogs is 8 weeks3.
1. Meadows et al. Parasites & Vectors 2014, 7:375
2. Rohdich et al. Parasites & Vectors 2014, 7:83
3. Bravecto chewable tablets summary of product characteristics -
Can Bravecto® be used in epilepsy?
As per the Bravecto Chewable tablet SPC and datasheet, use with caution in dogs with pre-existing epilepsy.
The statement was included as it represented a very rare occurrence captured in the Pharmacovigilance data reports. This does not demonstrate a causal relationship between Bravecto and seizures. Breakthrough seizures in animals under treatment for epilepsy is fairly normal according to key opinion1. We have no specific safety or efficacy concerns with these dogs and Bravecto has an established safety profile. Bravecto can be used with caution following a vet assessment as with any prescription. A dog with epilepsy can experience a seizure due to a wide range of stimuli, and thus caution is always in order.
1. Potschka et al., 2015. International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy. BMC Veterinary Research volume 11, Article number: 177.
-
Swapping to Bravecto® from another flea treatment
There are no known incompatibilities with other classes of ectoparasiticides or parasiticide. It would be a reasonable precaution to observe a normal retreatment interval after the use of another product in the same class (isoxazoline +/- macrocyclic lactone). If 2 products are being administered together, ensure they are applied at separate sites if they are spot-ons, and if it is their first use in that patient, ideally give on separate days.
-
Bravecto® and Environmental impact
MSD Animal Health conducts environmental risk assessments on its products from the development phase through product launch to understand and manage product impacts from manufacturing and patient use. Our environmental risk assessments are conducted in accordance with applicable stringent global regulations, including the regulatory review processes of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Product environmental safety profiles are reassessed during periodic renewals of product filings and risk mitigation actions are implemented when needed.
The potential transfer of active ingredients used in our spot-on and chew products from the dog into surface water has been assessed in the European environmental risk assessments. Based on their intrinsic properties we are confident in the absence of transfer into surface water for the active ingredients in the registered products in our companion animal line. However, please be aware of the statement on the Summary of Product Characteristics that dogs treated with Bravecto Spot-On should not be allowed to be immersed in water or swim in water courses within 3 days after treatment. There is no specifically identified risk to fish or aquatic species from this activity.
Following oral treatment of dogs fluralaner will mainly be excreted via the faeces, thus exposure of bees to fluralaner is considered very unlikely. Overall, there were no environmental concerns identified in the regulatory submissions or reviews. The environmental exposure through the oral treatment of dogs is considered too low to impact the environment.
-
What are the excipients in Bravecto® chewable tablets for Dogs?
The excipients in the Bravecto chewable tablets for Dogs are: pork liver flavour, sucrose, maize starch, sodium lauryl sulfate, disodium pamoate monohydrate, magnesium stearate, aspartame, glycerol, soya-bean oil and macrogol 3350.
-
What is the last day that Bravecto® can be given?
The expiry date of the product is stated on the packaging and refers to the last day of that month. Do not use the product after the expiry date.
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: February 2026